not in use here
25 Katholieke Universiteit Leuven, BE
Role and Contribution
In the clinical trials the investigators will follow dendritic cell distribution/migration after daily repeated inguinal intranodal injections (two cycles of four injections 4-6 week apart) in patients with primary liver cancer, melanoma and renal cell carcinoma. The patients are pretreated with low dose cyclophosphamide and given IFN regimens. Dendritic cells in the clinical setting will be marked with 111-In and/or ferromagnetic SPIO to be monitored by scintigraphy and/or MRI. The group at CUN will also operate the PET equipment and synthetize the radioactive compounds used for PET imaging. This will chiefly include [18F]FHBG to trace HSV1-tk expressing DC in preclinical models.
www.kuleuven.be
www.kuleuven.be
Staff
Uwe Himmelreich
Uwe is Associate Professor at the Department of Medical and Diagnostic Sciences of the Medical Faculty of K.U.Leuven. He is the head of the Biomedical NMR Unit and the management committee of the Molecular Small Animal Imaging Center at K.U.Leuven. Responsibility within ENCITE: development and evaluation of contrast mechanisms for non-invasive cell visualisation in disease and therapy models.
Uwe is Associate Professor at the Department of Medical and Diagnostic Sciences of the Medical Faculty of K.U.Leuven. He is the head of the Biomedical NMR Unit and the management committee of the Molecular Small Animal Imaging Center at K.U.Leuven. Responsibility within ENCITE: development and evaluation of contrast mechanisms for non-invasive cell visualisation in disease and therapy models.